TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00687193

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID, 3 blinded tablets administered BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10mg BID, 3 blinded tablets administered BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 15mg BID, 3 blinded tablets administered BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 1mg BID, 3 blinded tablets administered BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 3mg BID, 3 blinded tablets administered BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5mg BID, 3 blinded tablets administered BID for 12 weeks
Study: NCT04632680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVI followed by targeting of drivers
Description: Patients will undergo intraprocedural ECG-I mapping. The pulmonary veins will be isolated followed by targeting of drivers aiming to terminate AF.
Study: NCT03955146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Description: Pamrevlumab will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Description: Pamrevlumab will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Description: Pamrevlumab will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Description: Pamrevlumab will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to pamrevlumab will be administered per schedule specified in the arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to pamrevlumab will be administered per schedule specified in the arm description.
Study: NCT01891253

Intervention type: DEVICE
Intervention: non-invasive determination of cardiac output
Study: NCT00791934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratus Microflow Ethmoid Spacer
Description: The Spacer is inserted surgically into the ethmoid complex through the use of a sinus access system. Triamcinolone acetonide will be administered into the Spacer for this investigational study. The Spacer will be left in the ethmoid sinus for a period of 28 days. At the end of the implant period, the device is removed with standard instrumentation, during a follow-up office visit.
Study: NCT00495196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental lung function test
Description: Administration of several CO2 gas mixtures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental lung function test
Description: Administration of several CO2 gas mixtures
Study: NCT03793946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AB-assistant
Description: The AB-assistant is an antimicrobial stewardship smartphone application that offers local antimicrobial guidelines to physicians currently assessed per website or paper/digital booklet.
Study: NCT02718404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR-HIFU Treatment
Description: The Philips MR-HIFU Sonalleve System integrates a high intensity phased array focused ultrasound transducer with a 3 Tesla Magnetic Resonance (MR) imaging system and electromechanical transducer positioning system to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively.~At HIFU day (day 0) before treatment patient will be performed a bone lesion MRI and a functional brain MRI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR contrast media and medications
Description: During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR images
Description: Following the MR-HIFU procedure, a set of MR images of the target region will be acquired with the use of a MR contrast agent, together with a functional brain MRI.
Study: NCT04501042

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Bariatric surgery

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Bariatric surgery
Study: NCT04638543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-671
Description: ABP-671 Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00359645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screening by head and neck clinical examination with a fiberoptic nasolaryngoscopy and an oesopharyngeal brush biopsy annually during 3 years
Study: NCT02067078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg + Clonidine 75 microgram + Marcaine 90 mg + Adrenaline 90 microgram
Description: Dexamethasone 4 mg Clonidine 75 microgram Marcaine 90 mg Adrenaline 90 microgram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg + Clonidine 37,5 microgram + Marcaine 45 mg + Adrenaline 45 microgram
Description: Dexamethasone 2 mg Clonidine 37,5 microgram Marcaine 45 mg Adrenaline 45 microgram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine + Toradol + Adrenaline
Description: Ropivacaine 300 mg + Toradol 45 mg + Adrenaline 0,75 mg
Study: NCT03768492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine anhydrous 5% added to Lipoderm Cream Base.
Description: Caffeine USP Anhydrous 5 gm Ethoxy Digylco Reagent 10 ml Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
Study: NCT02936167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmalyte
Study: NCT03768492

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lipoderm Cream Base
Description: Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
Study: NCT02971748

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02920632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online cognitive training 1
Description: Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online cognitive training 2
Description: Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
Study: NCT04088149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GXNPC1
Description: Autologous ADSCs
Study: NCT03312231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: Oil-in-water emulsion based adjuvant system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: Oil-in-water emulsion based adjuvant system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: Oil-in-water emulsion based adjuvant system.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza H7N9 vaccine
Description: Monovalent 2017 H7N9 inactivated influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza H7N9 vaccine
Description: Monovalent 2017 H7N9 inactivated influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza H7N9 vaccine
Description: Monovalent 2017 H7N9 inactivated influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza H7N9 vaccine
Description: Monovalent 2017 H7N9 inactivated influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza H7N9 vaccine
Description: Monovalent 2017 H7N9 inactivated influenza vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Diluent for 2017 Monovalent Inactivated Influenza A/H7N9 virus vaccine (2017 H7N9 IIV)
Study: NCT03351764

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham TMS
Description: Subjects receive sham TMS via coil designed to produce the clicking sound of active TMS without delivering the magnetic field to the brain.

Intervention type: DEVICE
Group type: OTHER
Intervention: TMS
Description: non-invasive transcranial magnetic stimulation is used to temporarily modulation ongoing cortical activity
Study: NCT04097938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667 oral suspension
Description: GLPG3667 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667 oral suspension
Description: GLPG3667 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667 oral suspension
Description: GLPG3667 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667 oral suspension
Description: GLPG3667 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667 oral suspension
Description: GLPG3667 oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667 capsules
Description: GLPG3667 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667 capsules
Description: GLPG3667 capsules
Study: NCT04570930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive intervention (JITAI)
Description: JITAI is an emerging intervention that incorporates passive mobile sensor data feedback (sleep and activity \[step\] data from a Fitbit ®), and real-time self-reporting of HRQOL via a study specific app called CareQOL to provide personalized feedback via app alert.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will wear the Fitbit® and provide daily reports of HRQOL over a six-month (180 day) period.
Study: NCT01367106

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Euglycemic hyperinsulinemic clamp
Description: Euglycemic hyperinsulinemic clamp will be performed at day 2
Study: NCT01293487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RN564
Description: Intravenous, single dose with experimental dose
Study: NCT04709315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexemedetomidine and rocuronium
Description: In the DR group, patients received pretreatment with Dex 1 µg / kg in 10 ml 0.9% saline over 10 minutes and rocuronium 0.6 mg/kg was the intubating muscle relaxant
Study: NCT01367106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Euglycemic hyperinsulinemic clamp
Description: Euglycemic hyperinsulinemic clamp will be performed at day 2
Study: NCT04709315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline and succinyl choline 1mg/ kg
Description: 0.9% saline over 10 minutes, and succinyl choline 1mg/ kg
Study: NCT04314284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Can PIC
Description: -Online decision tool that explains health insurance terms and health insurance terms, provides tips on lowering health care costs, advises patient to discuss costs with provider and insurance, and provides financial resources for patient.

Intervention type: OTHER
Group type: OTHER
Intervention: Historical control survey
Description: -31 questions including overall experience with cancer care provider, previous discussions with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, confidence in health care choices and health insurance choices, current health conditions, and demographic data.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-intervention survey (I Can PIC participants)
Description: -31 questions including overall experience with cancer care provider, previous discussions with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, confidence in health care choices and health insurance choices, current health conditions, and demographic data.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-Up survey (I Can PIC participants)
Description: -19 questions including overall experience with cancer care provider, discussion with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, and confidence in health care choices and health insurance choices.
Study: NCT01655459

Intervention type: PROCEDURE
Intervention: Ultrasound exam of upper airway
Description: LMA-position was evaluated with fiberoptic laryngoscopy. The ultrasound findings of pre- and post-LMA were compared.
Study: NCT02842619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BonoFill-II
Description: Sinus augmentation - Surgery will be performed by either open or close sinus augmentation as per investigator discretion and as per common medical practice. After the elevation, BonoFill-II will be transplanted on the residual sub-antral bone.~Bone grafting after removal of cysts from jaws - Treatment will be performed according to the size of the cyst: in relatively small cyst total enucleation will be performed. In large cysts, a process of marsupialization will be performed. The entire cyst will be removed, including the epithelium layer, and the BonoFill-II product will be used for filling.
Study: NCT04249999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ActivOnline
Description: Access to online physical activity platform (www.activonline.com.au)
Study: NCT02996565

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice Clinic-Based Care
Description: Relies primarily on the physician-medical assistant dyad and face-to-face visits to promote:~1. Improved recognition of uncontrolled BP at primary care encounters,~2. Therapeutic action to address uncontrolled BP at primary care encounters,~3. Reliable follow-up visits to re-assess uncontrolled BP every 2-4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth Care
Description: All elements of Clinic-Based Care are performed, plus a telemonitoring and pharmacist case management program is offered, specifically:~1. Referral to care by MTM pharmacist or Nurse Practitioner and receiving a home blood pressure telemonitoring device~2. Systematic home BP telemonitoring with data transmitted into patient medical record~3. Systematic home-based care by pharmacist or nurse practitioner via telephone and/or secure email
Study: NCT04405349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.16
Description: Vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenously infusion
Study: NCT03030586

Intervention type: OTHER
Intervention: volumetric MRI

Intervention type: OTHER
Intervention: volumetric MRI

Intervention type: OTHER
Intervention: volumetric MRI
Study: NCT03135327

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ocufolin
Description: Ocufolin medical food capsules will be taken once a day by mouth each morning with a meal for the first week, two capsules orally each morning with a meal for the second week and three capsules orally each morning with a meal for the rest of the 6 months study duration.
Study: NCT04673253

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive leg Raise
Description: The intervention will be performed immediately after spinal anesthesia, and passive leg raise will be performed using two standard pillows placed under the heel so that the leg is approximately 30 cm above the horizontal plane of the table. The passive leg raising position will continue until the cord is clamped.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: The controlled group was positioned in the normal supine position.
Study: NCT02627729

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Linear cutter-Circular stapler
Description: a 5 to 6 cm-long colonic pouch will be created with a 80 mm linear cutting-closing stapler. The anastomosis of j-pouch will be routinely strengthened with 3:0 vicryl sutures. Then, a pouch to anal anastomosis will be performed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Circular stapler
Description: a 5 to 6 cm-long colonic segment will be left at the distal part and a side-to-end anastomosis will be performed.
Study: NCT01642251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study: NCT04401813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308 200mg
Description: Received IBI310 combined with sintilizumab 200mg
Study: NCT03052829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Description: Subjects in this arm will receive counseling on how to increase their physical activity level.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Subjects will undergo their usual care without intervention
Study: NCT03205423

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: Maintenance medication under investigation for its ability to alter the subjective and reinforcing effects of experimenter-administered doses of oxycodone and alcohol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Maintenance medication under investigation for its ability to alter the subjective and reinforcing effects of experimenter-administered doses of oxycodone and alcohol.
Study: NCT04158362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: Paclitaxel is administrated at the dose of 80 mg/m² as a 1-hour intravenous infusion every week (i.e., D1, D8 and D15) of a 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine tablets
Description: Capecitabine is given orally at a dose of 2000 to 2500 mg/m² daily for 14 days followed by a 7-day rest period every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Letrozole is administered orally at 2.5 mg/day continuous for patients nonsteroidal aromatase inhibitor naïve or relapsing \>1 year after the end of adjuvant endocrine therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole 1mg
Description: Anastrozole is administered orally at 1 mg/day continous for patients nonsteroidal aromatase inhibitor (NSAI) naïve or relapsing \>1 year after the end of adjuvant endocrine therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant Prefilled Syringe
Description: Fulvestrant is administered at the dose of 500 mg intramuscular on D1-D15-D29 (as a loading dose), and then 500 mg every 28 days (as a maintenance dose) for patients relapsing on adjuvant or less than one year after completion of adjuvant NSAI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Oral 150 mg BID continuous
Study: NCT04400643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTELLiVENT-ASV
Description: INTELLiVENT-ASV is software accessory that automatically adjust ventilation and oxygenation variables to keep the patient within clinician-set target ranges.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-automated ventilation
Description: In conventional ventilation modes, clinicians adjust and modify the oxygenation and ventilation parameters manually.
Study: NCT00791635

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT01642251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo of Veliparib
Study: NCT01732159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist
Description: he checklist will be administered to the patients by phone between 7 and 3 days before the surgery
Study: NCT00574613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P144
Description: Cream 0,3 ml once a day (3 months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Cream 0,3 ml once a day (3 months)
Study: NCT04580576

Intervention type: PROCEDURE
Intervention: Hematopoietic stem cell transplantation
Description: Allogeneic or autologous bone marrow transplant

Intervention type: PROCEDURE
Intervention: Hematopoietic stem cell transplantation
Description: Allogeneic or autologous bone marrow transplant
Study: NCT00819390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Taken orally, once daily, at a dose of 250 mg for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Taken orally, once daily, at a dose of 250 mg for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Study: NCT06603272

Intervention type: DEVICE
Intervention: The da Vinci robotic system (Intuitive Surgical, Inc., Sunnyvale, CA, USA) was used for all robotic gastrectomy
Description: Surgical intervention was initiated after obtaining informed consent from all patients, which included the additional costs of robotic surgery, a comprehensive explanation of surgical risks, and potential alternative treatments, thus facilitating informed surgical approach choices (i.e., LG or RG) within the participating institutions. Adherence to the Japanese Gastric Cancer Treatment Guidelines was maintained for determining the extent of gastrectomy and lymphadenectomy.